Specifically, Cycle will utilize Tepi Patch to develop formulations for rare neurological disorders such as dysphagia and dyskinesia. The companies will also be able to pursue developments of additional products. Benefits of Tepi Patch technology include less frequent drug administration, avoidance of gastrointestinal side effects, and improved patient compliance.

After the Tepi Patch formulations have been developed by Medherant, Cycle will be responsible for clinical development, registration, and commercialization of the products, according to the vendors.